A Prospective, Controlled, Randomized, Multicenter Study of the Efficacy of an Autophagy Inhibitor (GNS561), an Anti-NKG2A (Monalizumab) and an Anti-C5aR (Avdoralimab) Compared to the Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.
Latest Information Update: 04 Oct 2022
At a glance
- Drugs Avdoralimab (Primary) ; Ezurpimtrostat (Primary) ; Monalizumab (Primary) ; Nivolumab (Primary) ; Tocilizumab (Primary)
- Indications COVID 2019 infections; Haematological malignancies; Pneumonia; Solid tumours
- Focus Therapeutic Use
- Acronyms IMMUNONCOVID; IMMUNONCOVID-20
- 29 Sep 2022 Status changed from active, no longer recruiting to completed.
- 04 Aug 2021 Planned End Date changed from 1 Aug 2021 to 1 Dec 2021.
- 04 Aug 2021 Status changed to active, no longer recruiting.
Most Recent Events
Trial Overview
Purpose
A prospective, controlled, randomized, multicenter study whose goal is to compare the efficacy of an autophagy inhibitor (GNS561), an anti-NKG2A (monalizumab) and an anti-C5aR (avdoralimab) versus standard of care in patients with advanced or metastatic cancer who have Sars-CoV-2 infection not eligible to a resuscitation unit. According to their severity level at the time of enrolment, eligible patients will be randomized into 2 different cohorts: - COHORT 1 (mild symptoms or asymptomatic): GNS561 vs anti-NKG2A vs standard of care (randomization ratio 1:1:1). - COHORT 2 (moderate/severe symptoms): anti-C5aR vs standard of care (randomization ratio 1:1).
Primary Endpoints
28-day survival rate
description: 28-day survival rate, defined by the proportion of patients still alive 28 days after randomization.
If vital status at 28 days post randomisation is not available due to early transfer in an external resuscitation unit, patients will be considered as failure at the date of the transfer.
Comparison of each experimental arm (GNS561 then monalizumab for cohort1 and avdoralimab for cohort2) to control arm will be performed using a Fisher exact test.
time_frame: 28 days from randomization
Other Endpoints
Time to clinical improvement
description: Time to clinical improvement defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale (WHO-ISARIC) or live discharge from the hospital, whichever comes first.
time_frame: 28 days from randomization
Clinical status
description: Clinical status will be assessed using a 7-point ordinal scale :
Not hospitalized, no limitations on activities
Not hospitalized, limitation on activities;
Hospitalized, not requiring supplemental oxygen;
Hospitalized, requiring supplemental oxygen;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;
Hospitalized, on invasive mechanical ventilation or ECMO;
Death.
time_frame: Day 7, Day 14, Day 28
Clinical status
description: The NEWS2 score (National Early Warning Score) allocates a score based on six physiological parameters (respiratory rate / oxygen saturation / systolic blood pressure / heart rate / consciousness / temperature).
It Determines the degree of illness of a patient and prompts critical care intervention.
The total possible score ranges from 0 to 21. The higher the score, the greater the clinical risk. A total score close to 0 corresponds to a low risk and a total score higher than 7 corresponds to a high risk.
time_frame: Day 7, Day 14, Day 28
Mean change in the ranking on the ordinal scale from baseline to D7, D14 and D28
description: Mean change in clinical status from baseline will be assessed by using a 7-point ordinal scale.
time_frame: Day 7, Day 14, Day 28
Mean change in the ranking of the NEWS2 score from baseline to D7, D14 and D28
description: Mean change in clinical status from baseline will be assessed by using the NEWS2 score (National Early Warning Score).
The NEWS2 score (National Early Warning Score) allocates a score based on six physiological parameters (respiratory rate / oxygen saturation / systolic blood pressure / heart rate / consciousness / temperature).
It Determines the degree of illness of a patient and prompts critical care intervention.
The total possible score ranges from 0 to 21. The higher the score, the greater the clinical risk. A total score close to 0 corresponds to a low risk and a total score higher than 7 corresponds to a high risk.
time_frame: Day 7, Day 14, Day 28
Overall survival
description: Overall survival will be defined by the time from date of randomization until date of death, regardless of the cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.
time_frame: 3 months (i.e. at the time of last patient last visit)
Length of stay in Intensive Care Unit
description: The length of stay in Intensive Care Unit (from the date of admission in the Unit to the date of discharge).
time_frame: 3 months (i.e. at the time of last patient last visit)
Duration of mechanical ventilation or high flow oxygen devices
description: The duration of mechanical ventilation or high flow oxygen devices (from the date of intubation to the stop date of mechanical ventilation or high flow oxygen)
time_frame: 3 months (i.e. at the time of last patient last visit)
Duration of hospitalization
description: The duration of hospitalization (from the date of hospitalization to the date of definitive discharge for live patients)
time_frame: 3 months (i.e. at the time of last patient last visit)
Rate of throat swab negativation
time_frame: Day 7, Day 14, Day 28
Quantitative SARS-CoV-2 virus in throat swab and blood samples
time_frame: Day 7, Day 14, Day 28
The rate of secondary infection by other documented pathogens (bacteria, fungi)
time_frame: Day 7, Day 14, Day 28 (if available)
Biological parameters
description: Changes from baseline in neutrophils count (G/L)
time_frame: 3 months (i.e. at the time of last patient last visit)
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
description: Treatment-Emergent Adverse Events, Serious Adverse Events, Suspected Unexpected Serious Adverse Reactions, New Safety Issues described using the NCI-CTC AE classification v5.
Number of participants with a discontinuation or temporary suspension of study drugs (for any reason).
time_frame: 3 months (i.e. at the time of last patient last visit)
Cost-Effectiveness Analyses (CEA)
description: Incremental Cost-Effectiveness Ratios (ICERs) expressed in cost per Life Year Gained.
time_frame: 3 months (i.e. at the time of last patient last visit)
Biological parameters
description: Changes from baseline in lymphocytes count (G/L)
time_frame: 3 months (i.e. at the the time of last patient last visit)
Biological parameters
description: Changes from baseline in platelets count (G/L)
time_frame: 3 months (i.e. at the the time of last patient last visit)
Biological parameters
description: Changes from baseline in hemoglobin count (g/dL)
time_frame: 3 months (i.e. at the the time of last patient last visit)
Biological parameters
description: Changes from baseline in CRP count (mg/L)
time_frame: 3 months (i.e. at the the time of last patient last visit)
Biological parameters
description: Changes from baseline in pro-inflammatory cytokine (IL6)
time_frame: 3 months (i.e. at the the time of last patient last visit)
The rate of patients with SARS-CoV-2 IgG antibodies at D7, D14 and D28
time_frame: Day 7, Day 14, Day 28 [1]
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | treatment | - |
| Haematological malignancies | treatment | stage III, stage IV |
| Pneumonia | treatment | - |
| Solid tumours | treatment | stage III, stage IV |
Biomarker
| NCT Number | Biomarker Name | Biomarker Function |
|---|---|---|
| NCT04333914 | C-reactive protein (CRP) | Outcome Measure |
| Interleukin-6 (IL-6) | Outcome Measure |
Subjects
- Subject Type patients
-
Number
Planned: 273
Actual: 19
- Sex male & female
- Age Group ≥ 18 years
Patient Inclusion Criteria
I1. Age 18 or older at the time of enrolment for women and age 60 or older at the time of enrolment for men. I2. Histologically or cytologically confirmed diagnosis of advanced or metastatic hematological or solid tumor (hematological or solid tumor, any type and any localization). I3. Documented diagnosis of COVID-19 (diagnostic test performed in a certified laboratory) without indication of transfer in a rescucitation unit.; Nota Bene : A maximum time of 7 days may have elapsed between the date of first symptoms and the date of consent for patient cohort 1 (mild). In cohort 2 (severe), up to 10 days may have elapsed since the first symptoms. I4. Cohort 2: patients with pneumonia confirmed by chest imaging, and an oxygen saturation (Sao2) of 94% or less while they are breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) (Pao2:Fio2) at or below 300 mg Hg. I5. Multidisciplinary approach that patient is not eligible for a transfer to Resuscitation Unit (either due to underlying medical condition - including cancer - or due to lack of available bed). Note: Item cancelled (addendum 2 - October 2020) I6. Life-expectancy longer than 3 months. I7. Adequate bone marrow and end-organ function defined by the following laboratory results: - Bone marrow: - Hemoglobin ≥ 9.0 g/dL, - Absolute Neutrophils Count (ANC) ≥ 1.0 Gi/L, - Platelets ≥ 100 Gi/L; - Hepatic function: - Total serum bilirubin ≤ 1.5 x ULN (except patients with Gilbert's syndrome who must have total serum bilirubin ≤ 3.0 x ULN), - AST/ALT ≤ 5 ULN - Renal function: - Serum creatinine ≤ 2.0 x ULN or Cr. Cl. ≥ 30ml/min/1.73m² (MDRD or CKD-EPI formula); I8. Willingness and ability to comply with the study requirements; I9. Signed and dated informed consent indicating that the patient has been informed of all the aspects of the trial prior to enrollment (in case of emergency situation, please refer to protocol section 12.1 PATIENT INFORMATION AND INFORMED CONSENT); I10. Women of childbearing potential (Appendix 1) are required to have a negative serum pregnancy test within 72 hours prior to study treatment start. A positive urine test must be confirmed by a serum pregnancy test; I11. Women of childbearing potential and male patients must agree to use adequate highly effective contraception (Appendix 1) for the duration of study participation and up to 6 months following completion of therapy; I12. Patient must be covered by a medical insurance.
Patient Exclusion Criteria
E1. For cohort 1 only: Patient currently receiving therapy with an anti-NKG2A. E2. For cohort 2 only: Patient currently receiving therapy with an anti-C5aR. E3. Patient presents a contraindication to monalizumab treatment (cohort 1 only) or to avdoralimab (cohort 2 only) as per respective IB, including known hypersensitivity to one of these study drugs or severe hypersensitivity reaction to any monoclonal antibody. E4. For cohort 1 only: Patient known to have intolerance or hypersensitivity to chloroquine or any quinoline derivatives (quinine, chloroquine, tafenoquine, hydroxychloroquine, mefloquine). Patients previously exposed to CQ, HCQ or other quinoline derivates should have interrupted their treatment at least 72h prior to randomization. E5. Patient has active autoimmune disease that has required systemic treatment in the past 3 months before the date of randomisation or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids at doses higher than 10 mg/d prednisone equivalents or immunosuppressive agents. Note 1: Patients with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Patients that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Patients with hypothyroidism stable on hormone replacement or Sjögren's syndrome will not be excluded from the study. Note 2: Patients may received corticosteroids as required for the management of SARS-CoV-2-related symptoms. E6. Patient requires the use of one of the following forbidden treatment during the study treatment period, including but not limited to : - Major surgery - Live vaccines. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever and BCG. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed. E7. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to the date of randomisation unstable arrhythmias or unstable angina, Known Left Ventricular Ejection Fraction (LVEF) < 50%. Note: Patients with known coronary artery disease, congestive heart failure not meeting the above criteria must be on a stable medical regimen that is optimized in the opinion of the treating physician and in consultation with a cardiologist if appropriate. E8. Patient has known active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen [HBsAg] test at screening), known active hepatitis C (Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA at screening) or known Human Immunodeficiency Virus (HIV) infection (HIV 1/2 antibodies). E9. Prior allogeneic bone marrow transplantation or solid organ transplant in the past. E10. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator. E11. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. E12. Pregnant or breastfeeding patient, or expecting to conceive children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of study drugs.
Trial Details
Identifiers
| Identifier | Owner |
|---|---|
| NCT04333914 | ClinicalTrials.gov: US National Institutes of Health |
| EudraCT2020-001373-70 | European Clinical Trials Database |
| ET20-076 | - |
| ET20-076IMMUNONCOVID20 | - |
Organisations
- Affiliations Genoscience; Innate Pharma
Trial Dates
-
Initiation Dates
Planned : 01 Apr 2020
Actual : 15 Apr 2020
-
Primary Completion Dates
Planned : 01 Jun 2021
Actual : 06 Jul 2021
-
End Dates
Planned : 01 Dec 2021
Actual : 31 Dec 2021
Other Details
- Design cohort; multicentre; open; parallel; prospective; randomised
- Phase of Trial Phase II
- Location France
- Focus Therapeutic Use
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| AvdoralimabPrimary Drug | Intravenous |
-
|
| EzurpimtrostatPrimary Drug | Oral | Capsule |
| MonalizumabPrimary Drug | Intravenous | Infusion |
| NivolumabPrimary Drug | Intravenous | Infusion, Injection |
| TocilizumabPrimary Drug | Intravenous | Infusion, Injection |
Autophagy inhibitor (GNS651)
Drug: Autophagy inhibitor (GNS651) (Cohort 1 (arm B): 200mg q.d. orally for 10 consecutive days. If for any reason a treatment is not given within the allowed treatment window (± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day.) Other: Standard of care (In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation. Additional care and medications should be administered in the patient's best interest.)
Standard of care
Other: Standard of care (In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation. Additional care and medications should be administered in the patient's best interest.)
anti-C5aR (Avdoralimab)
Other: Standard of care (In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation. Additional care and medications should be administered in the patient's best interest.) Drug: Avdoralimab (Cohorte 2 (arm H): 500mg, intravenously, at Day 1 then 200mg once daily every 2 days during 14 Days)
anti-NKG2A (Monalizumab)
Other: Standard of care (In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation. Additional care and medications should be administered in the patient's best interest.) Drug: Monalizumab (Cohorte 2 (arm G) : 50mg (flat dose),intravenously, single infusion at Day 1.)
Trial Centres
Investigators
| Investigator | Centre Name | Trial Centre Country |
|---|---|---|
| Philippe CASSIER | Centre Leon Berard |
-
|
Centres
| Centre Name | Location | Trial Centre Country |
|---|---|---|
| AP-HP Hôpital Bichat Claude Bernard | Paris | France |
| AP-HP Hôpital Saint Antoine | Paris | France |
| AP-HP La Pitié Salpétrière | Paris | France |
| AP-HP Tenon | Paris | France |
| Centre Jean Perrin | Clermont-Ferrand | France |
| Centre Leon Berard |
-
|
-
|
| Centre Léon Bérard | Lyon, Rhône | France |
| Centre Oscar Lambret | Lille | France |
| CHU Clermont Ferrand | Clermont Ferrand | France |
| GH Diaconesses Croix Saint Simon | Paris | France |
| Hôpital Saint-Joseph | Paris | France |
| Institut de cancérologie Strasbourg Europe (ICANS) | Strasbourg | France |
| Institut Gustave Roussy | Villejuif | France |
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 04 Oct 2022 | Other trial event | Last checked against ClinicalTrials.gov record. Updated 04 Oct 2022 |
| 29 Sep 2022 | Status change - completed | Status changed from active, no longer recruiting to completed. Updated 04 Oct 2022 |
| 05 Aug 2021 | Biomarker Update | Biomarkers information updated Updated 04 Nov 2021 |
| 04 Aug 2021 | Completion date | Planned End Date changed from 1 Aug 2021 to 1 Dec 2021. Updated 09 Aug 2021 |
| 04 Aug 2021 | Status change - active, no longer recruiting | Status changed to active, no longer recruiting. Updated 09 Aug 2021 |
| 28 Jul 2021 | Other trial event | Last checked against European Clinical Trials Database record. Updated 28 Jul 2021 |
| 28 Jul 2021 | Status change - discontinued | Status changed from recruiting to discontinued. Updated 28 Jul 2021 |
| 02 Dec 2020 | Other trial event | Planned number of patients changed from 384 to 219. Updated 09 Dec 2020 |
| 02 Dec 2020 | Completion date | Planned End Date changed from 1 Aug 2020 to 1 Aug 2021. Updated 09 Dec 2020 |
| 02 Dec 2020 | Other trial event | Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021. Updated 09 Dec 2020 |
| 17 Nov 2020 | Status change - recruiting | Status changed from suspended to recruiting, according to an Innate pharma media release. Updated 29 Nov 2020 |
| 08 Sep 2020 | Other trial event | According to an Innate Pharma media release, the company obtained 6.8m euro in public funding from the French government for its COVID-19 R&D activities which will enable the Company to cover the development of its current COVID-19 activities including the EXPLORE COVID-19 translational research study and its two Phase 2 clinical trials, FORCE and ImmunONCOVID-20. Updated 09 Sep 2020 |
| 08 Sep 2020 | Other trial event | According to an Innate Pharma media release, the company continues to closely monitor the situation and is also assessing the feasibility to expand its exploration of avdoralimab in COVID-19 into other geographies. Updated 09 Sep 2020 |
| 12 Jun 2020 | Status change - suspended | Status changed from recruiting to suspended due to potential recruitment related to the epidemic context. Updated 17 Jun 2020 |
| 05 Jun 2020 | Protocol amendment | Trial protocol has been amended as Number of arms has been increase from 4 to 6 or planned patient number increases. Updated 10 Jun 2020 |
| 05 Jun 2020 | Other trial event | Planned number of patients changed from 273 to 384. Updated 10 Jun 2020 |
| 13 Apr 2020 | Other trial event | New source identified and integrated European Clinical Trials Database (EudraCT2020-001373-70). Updated 13 Apr 2020 |
| 07 Apr 2020 | New trial record | New trial record Updated 07 Apr 2020 |
| 03 Apr 2020 | Status change - recruiting | Status changed from not yet recruiting to recruiting. Updated 08 Apr 2020 |
References
-
ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2023;.
Available from: URL: http://clinicaltrials.gov -
European Clinical Trials Database. Trial-Reg 2023;.
Available from: URL: https://www.clinicaltrialsregister.eu -
HemaCare Corporation. HemaCare Supports 2016 CAR-TCR Summit. Media-Rel 2016;.
Media Release -
Innate Pharma. Innate Pharma Reports Third Quarter 2020 Financial Results and Business Update. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG